Cargando…

Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases

BACKGROUND: While different COVID-19 vaccines have been developed, there has been lack of data on the efficacy comparison between mRNA and inactivated whole virus vaccine among patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and bronchiecta...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwok, Wang Chun, Leung, Sze Him Isaac, Tam, Terence Chi Chun, Ho, James Chung Man, Lam, David Chi-Leung, Ip, Mary Sau Man, Ho, Pak Leung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869785/
https://www.ncbi.nlm.nih.gov/pubmed/36698687
http://dx.doi.org/10.2147/COPD.S394101
_version_ 1784876839537213440
author Kwok, Wang Chun
Leung, Sze Him Isaac
Tam, Terence Chi Chun
Ho, James Chung Man
Lam, David Chi-Leung
Ip, Mary Sau Man
Ho, Pak Leung
author_facet Kwok, Wang Chun
Leung, Sze Him Isaac
Tam, Terence Chi Chun
Ho, James Chung Man
Lam, David Chi-Leung
Ip, Mary Sau Man
Ho, Pak Leung
author_sort Kwok, Wang Chun
collection PubMed
description BACKGROUND: While different COVID-19 vaccines have been developed, there has been lack of data on the efficacy comparison between mRNA and inactivated whole virus vaccine among patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis. METHODS: This was a retrospective case control study on the efficacy of BNT162b2 (mRNA vaccine) and CoronaVac (inactivated whole virus vaccine) against COVID-19 in patients with chronic respiratory diseases. A total of 327 patients were included, with 109 patients infected with COVID-19 matched with 218 patients without COVID-19. The co-primary outcomes were vaccine effectiveness against symptomatic COVID-19, COVID-19-related hospitalization and COVID-19-related respiratory failure. Vaccine effectiveness was calculated using the formula (1-adjusted odds ratio) x 100. RESULTS: Patients who received at least 2 doses of CoronaVac had lower risk of being hospitalized for COVID-19 and developing respiratory failure than those who did not have vaccination, with adjusted odds ratio (OR) of 0.189 (95% CI = 0.050–0.714, p = 0.014) and 0.128 (95% CI = 0.026–0.638, p = 0.012) respectively. Patients who received at least 2 doses of BNT162b2 had lower risk of being hospitalized for COVID-19 and developing respiratory failure than those who did not have vaccination with adjusted OR of 0.207 (95% CI = 0.043–0.962, p = 0.050) and 0.093 (95% CI = 0.011–0.827, p = 0.033) respectively. There was no statistically significant difference in the risks of being hospitalized for COVID-19 and developing respiratory failure between patients who received at least 2 doses of CoronaVac or BNT162b2. CONCLUSION: BNT162b2 and CoronaVac vaccines are effective in preventing hospitalization for COVID-19 and respiratory failure complicating COVID-19 among patients with chronic respiratory diseases. Patients with chronic respiratory diseases should be encouraged to have COVID-19 vaccination.
format Online
Article
Text
id pubmed-9869785
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-98697852023-01-24 Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases Kwok, Wang Chun Leung, Sze Him Isaac Tam, Terence Chi Chun Ho, James Chung Man Lam, David Chi-Leung Ip, Mary Sau Man Ho, Pak Leung Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: While different COVID-19 vaccines have been developed, there has been lack of data on the efficacy comparison between mRNA and inactivated whole virus vaccine among patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis. METHODS: This was a retrospective case control study on the efficacy of BNT162b2 (mRNA vaccine) and CoronaVac (inactivated whole virus vaccine) against COVID-19 in patients with chronic respiratory diseases. A total of 327 patients were included, with 109 patients infected with COVID-19 matched with 218 patients without COVID-19. The co-primary outcomes were vaccine effectiveness against symptomatic COVID-19, COVID-19-related hospitalization and COVID-19-related respiratory failure. Vaccine effectiveness was calculated using the formula (1-adjusted odds ratio) x 100. RESULTS: Patients who received at least 2 doses of CoronaVac had lower risk of being hospitalized for COVID-19 and developing respiratory failure than those who did not have vaccination, with adjusted odds ratio (OR) of 0.189 (95% CI = 0.050–0.714, p = 0.014) and 0.128 (95% CI = 0.026–0.638, p = 0.012) respectively. Patients who received at least 2 doses of BNT162b2 had lower risk of being hospitalized for COVID-19 and developing respiratory failure than those who did not have vaccination with adjusted OR of 0.207 (95% CI = 0.043–0.962, p = 0.050) and 0.093 (95% CI = 0.011–0.827, p = 0.033) respectively. There was no statistically significant difference in the risks of being hospitalized for COVID-19 and developing respiratory failure between patients who received at least 2 doses of CoronaVac or BNT162b2. CONCLUSION: BNT162b2 and CoronaVac vaccines are effective in preventing hospitalization for COVID-19 and respiratory failure complicating COVID-19 among patients with chronic respiratory diseases. Patients with chronic respiratory diseases should be encouraged to have COVID-19 vaccination. Dove 2023-01-19 /pmc/articles/PMC9869785/ /pubmed/36698687 http://dx.doi.org/10.2147/COPD.S394101 Text en © 2023 Kwok et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Kwok, Wang Chun
Leung, Sze Him Isaac
Tam, Terence Chi Chun
Ho, James Chung Man
Lam, David Chi-Leung
Ip, Mary Sau Man
Ho, Pak Leung
Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases
title Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases
title_full Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases
title_fullStr Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases
title_full_unstemmed Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases
title_short Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases
title_sort efficacy of mrna and inactivated whole virus vaccines against covid-19 in patients with chronic respiratory diseases
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869785/
https://www.ncbi.nlm.nih.gov/pubmed/36698687
http://dx.doi.org/10.2147/COPD.S394101
work_keys_str_mv AT kwokwangchun efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases
AT leungszehimisaac efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases
AT tamterencechichun efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases
AT hojameschungman efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases
AT lamdavidchileung efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases
AT ipmarysauman efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases
AT hopakleung efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases